Year None2022202120202019 Sep 26, 2022 Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0 Sep 20, 2022 Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DE Sep 09, 2022 New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatit Sep 07, 2022 Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd. Sep 06, 2022 New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Der Sep 02, 2022 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 02, 2022 Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors Sep 01, 2022 Arcutis to Present at Upcoming Investor Conference Aug 30, 2022 New Campaign from Arcutis Aims to Expose the Impact of Psoriasis on Physical, Mental, and Emotional Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 9 of 36
